drugset / Trial / NCT07487740

A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

NCT07487740

Phase 1 Recruiting 60 enrolled Trevi Therapeutics
RandomizedCrossoverOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the effect of a high-fat, high-calorie meal on the relative bioavailability of NAL ER following single oral doses.

Timeline

Start
2026-02-27
Primary completion
2026-04
Completion
2026-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Nalbuphine Small molecule Oral

Indications

No indication recorded.